The increasing geriatric population and high demand for vaccine development during the COVID-19 emergence boosts the growth of the lentiviral vector market. The increase in genetic abnormalities and infectious diseases is also increasing the viral vector generation. As per the Joint United Nations Programme on HIV/AIDS (UNAIDS) Statistics, around 27.5 million people worldwide were surviving with HIV in 2020. Numerous private and government-funded initiatives focused primarily on research and development projects that are expected to promote market expansion.
Data Bridge Market Research analyses that the Global Lentiviral Vector Market which is USD 10.30 million in 2022, and is expected to reach USD 25.32 million by 2030, at a CAGR of 11.9% during the forecast period 2023 to 2030. The increasing demand for the lentiviral vector will provide potential opportunities for the market growth in the forecast period.
Increasing demand of viral vectors is anticipated to drive the market's growth rate
The wide introduction of innovative therapies such as gene therapy, which uses numerous viral and non-viral vectors to treat various heritable and acquired diseases, has paved the way for the treatment of these diseases that lacked effective treatment options. The increased number of clinical trials on viral vector-mediated gene therapy shows the rising preference for viral vectors in gene transfer, further improving its demand in the market.
For instance,
- In 2019, as per the first quarter report of Alliance for Regenerative Medicine (ARM), it had been witnessed that the 372 clinical trials were performed involving vector-mediated gene therapy production. It has also been witnessed that the number of gene therapy clinical trials increased by 2018.
Report Scope and Market Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Years
|
2021 (Customizable to 2015 - 2020)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Component (Lentiviral promoter, Lentiviral fusion tags, Lentivirus packaging systems and Other), Type (Product and Services), Generation (4th-generation, 3rd-generation, 2nd-generation and 1st-generation), Workflow (Upstream Processing And Downstream Processing), Delivery Method (In Vivo and Ex Vivo), Disease Indication (Cancer, Genetic Disorders, Infectious Diseases, Veterinary Disease And Other), Application (Gene Therapy And Vaccinology), End User (Biotechnology Companies, Pharmaceutical Companies, Contract Research Organizations, Contract Development and Manufacturing Organization (CDMO) and Academic/Research Institutes)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
Cobra Biologics Limited (U.K.), Sirion-Biotech GmbH (Germany), Merck KGaA (Germany), FinVector Oy (Finland), Oxford Biomedica (U.K.), OriGene Technologies, Inc. (U.S.), Sino Biological Inc. (China), Cell Biolabs, Inc. (U.S.), Batavia Biosciences B.V. (Netherlands), Lonza (Switzerland), GENEMEDI (China), Takara Bio Inc. (Japan), Thermo Fisher Scientific Inc. (U.S.), Waisman Biomanufacturing (U.S.), and Cytiva (U.S.)
|
|
Data Points Covered in the Report
|
In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include in-depth expert analysis, geographically represented company-wise production and capacity, network layouts of distributors and partners, detailed and updated price trend analysis and deficit analysis of supply chain and demand
|
Segment Analysis:
Global lentiviral vector market is categorized into eight notable segments which are based on the component, type, generation, workflow, delivery method, disease indication, application and end user.
- On the basis of component, global lentiviral vector market is segmented into lentiviral promoter, lentiviral fusion tags, lentivirus packaging systems and other.
The lentivirus packaging systems segment of component type is anticipated to dominate the lentiviral vector market
The lentivirus packaging systems segment is expected to dominate the market with 48.96% market share due to the increasing number of research and development globally.
- On the basis of type, global lentiviral vector market is segmented into product and services.
The product segment of type is anticipated to dominate the lentiviral vector market
The product segment is expected to dominate the market with 58.29% market share because of the increasing prevalence of infectious diseases.
- On the basis of generation, global lentiviral vector market is segmented into 4th-generation, 3rd-generation, 2nd-generation and 1st-generation. The 4th-generation segment is expected to dominate the market with 36.71% market share because of the advanced codon optimization technology being used in vector production with stable integration and high yield formation
- On the basis of workflow, global lentiviral vector market is segmented into upstream processing and downstream processing. The upstream processing segment is expected to dominate the market with 69.23% market share due to increasing investment for R&D activities by major healthcare organizations
- On the basis of delivery method, global lentiviral vector market is segmented into in vivo and ex vivo. The in vivo segment is expected to dominate the market with 63.37% market share because of its high availability and process reliability.
- On the basis of disease indication, global lentiviral vector market is segmented into cancer, genetic disorders, infectious diseases, veterinary disease and other. The cancer segment is expected to dominate the market with 36.20% market share to the increasing incidence and incidence of genetic disorders.
- On the basis of application, global lentiviral vector market is segmented into gene therapy and vaccinology. The gene therapy segment is expected to dominate the market with 73.35% market share due to wide range of applications in the medical sector.
- On the basis of end user, global lentiviral vector market is segmented into biotechnology companies, pharmaceutical companies, contract research organizations, contract development and manufacturing organization (CDMO) and academic/ research institutes. The academic/ research institutes segment is expected to dominate the market with 47.88% market share due to growing initiative activities by numerous healthcare organizations and government bodies.
Major Players
Data Bridge Market Research recognizes the following companies as the major lentiviral vector market players in lentiviral vector market are Cobra Biologics Limited (U.K.), Sirion-Biotech GmbH (Germany), Merck KGaA (Germany), FinVector Oy (Finland), Oxford Biomedica (U.K.), OriGene Technologies, Inc. (U.S.), Sino Biological Inc. (China), Cell Biolabs, Inc. (U.S.), Batavia Biosciences B.V. (Netherlands), Lonza (Switzerland), GENEMEDI (China), Takara Bio Inc. (Japan), Thermo Fisher Scientific Inc. (U.S.), Waisman Biomanufacturing (U.S.), and Cytiva (U.S.).
Market Development
- In 2020, Waisman Biomanufacturing partnered with the California-based biotech company GigaGen to develop a new drug for treating and preventing COVID-19. The aim was to increase the use of development and testing of new types of drugs by Waisman Biomanufacturing, leading to increased market awareness of its services.
- In 2021, Oxford Biomedica entered into a new three-year Development & Supply Agreement with Boehringer Ingelheim to manufacture and supply viral vectors. This agreement is anticipated to increase the company's sales growth in the coming years.
- In 2021, Cobra Biologics Limited collaborated with an emerging leader of a recombinant human albumin company called Albumedix. The motive was to improve their product Lentivirus Vector and AAV manufacturing. This enhanced their company profile and sales for the future market
Regional Analysis
Geographically, the countries covered in the lentiviral vector market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
As per Data Bridge Market Research analysis:
North America is the dominant region in lentiviral vector market during the forecast period 2023 to 2030
North America dominates the lentiviral vector market due to high distribution in the U.S. industries required for analytical process. The rapidly increasing number of advanced therapy products entering clinical trials and the presence of major regional operating players.
Asia-Pacific is estimated to be the fastest-growing region in lentiviral vector market the forecast period 2023 to 2030
Asia-Pacific is expected to grow during the forecast period of 2023 to 2030 because of the increasing incidence of cancer of bladder, pancreas and the high presence of major manufacturers across the U.S. Moreover, increased efforts for COVID-19 vaccine development in the country led to significant growth, subsequently exhibiting the fastest CAGR for the region.
For more detailed information about lentiviral vector market report, click here – https://www.databridgemarketresearch.com/de/reports/global-lentiviral-vector-market
